We are live on
!
Find out more
CA
CHI Advisors Portfolio holdings
AUM
$252M
1-Year Est. Return
56.99%
This Fund
S&P 500
This Quarter
Est. Return
-4.46%
1 Year Est. Return
+56.99%
3 Year Est. Return
+88.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$262M
AUM Growth
+$26.7M
(+11%)
Cap. Flow
+$49.5M
Cap. Flow
% of AUM
18.91%
Top 10 Holdings %
Top 10 Hldgs %
82.76%
Holding
28
New
6
Increased
13
Reduced
2
Closed
–
Avg Time Held Equity + Options
5.3
quarters
Top 10 Avg Time Held Equity + Options
3.2
quarters
Top 20 Avg Time Held Equity + Options
5.8
quarters
Avg Time Held Equity only
5.9
quarters
Top 10 Avg Time Held Equity only
3.2
quarters
Top 20 Avg Time Held Equity only
5.8
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kezar Life Sciences
KZR
|
+$13.5M |
| 2 |
Inozyme Pharma
INZY
|
+$4.97M |
| 3 |
Nkarta
NKTX
|
+$4.7M |
| 4 |
Precision BioSciences
DTIL
|
+$4.69M |
| 5 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
+$3.76M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ONCR
Oncorus, Inc.
ONCR
|
+$67.9K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.85% |
| 2 | Miscellaneous | 0.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
RXDX
1
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $47.2M | 18.03% |
1,671,976
+86,880
| +5% | +$2.52M |
2021 Q1
5 quarters
|
|
2
Cullinan Oncology
CGEM
$964M
| $39.1M | 14.92% |
3,047,609
+294,562
| +11% | +$3.34M |
2021 Q1
5 quarters
|
|
3
DELISTED
Repare Therapeutics
RPTX
| $37M | 14.14% |
2,646,781
+65,684
| +3% | +$773K |
2020 Q2
8 quarters
|
|
4
Pliant Therapeutics
PLRX
$61.3M
| $24.9M | 9.5% |
3,106,807
+449,350
| +17% | +$2.88M |
2020 Q2
8 quarters
|
|
|
VECT
5
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| $20.4M | 7.8% |
3,782,199
+697,889
| +23% | +$3.76M |
2021 Q2
4 quarters
|
|
|
6
DELISTED
Kezar Life Sciences
KZR
| $15.2M | 5.81% |
184,079
+152,618
| +485% | +$13.5M |
2019 Q3
11 quarters
|
|
7
DELISTED
2seventy bio
TSVT
| $10.8M | 4.13% |
819,672
| – | – |
2022 Q1
1 quarter
|
|
|
8
DELISTED
Inozyme Pharma
INZY
| $9.7M | 3.71% |
2,033,802
+1,141,745
| +128% | +$4.97M |
2020 Q3
7 quarters
|
|
9
Compass Therapeutics
CMPX
$169M
| $7.5M | 2.86% |
2,829,712
| – | – |
2021 Q4
2 quarters
|
|
10
ImageneBio Inc
IMA
$48.2M
| $4.83M | 1.85% |
90,911
+23,015
| +34% | +$1.27M |
2021 Q1
5 quarters
|
|
|
11
Precision BioSciences
DTIL
$180M
| $4.81M | 1.84% |
100,125
+79,904
| +395% | +$4.69M |
2019 Q3
11 quarters
|
|
|
12
Nkarta
NKTX
$155M
| $4.41M | 1.68% |
+358,013
| New | +$4.7M |
2022 Q2
0 quarters
|
|
|
FRLN
13
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
| $4.23M | 1.62% |
324,155
| – | – |
2020 Q3
7 quarters
|
|
14
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
| $4.01M | 1.53% |
1,055,882
| – | – |
2021 Q3
3 quarters
|
|
|
AKUS
15
DELISTED
Akouos Inc
AKUS
| $3.92M | 1.5% |
836,120
| – | – |
2020 Q2
8 quarters
|
|
16
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $3.79M | 1.45% |
767,235
+278,600
| +57% | +$1.54M |
2020 Q2
8 quarters
|
|
|
ORTX
17
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $3.1M | 1.18% |
530,775
| – | – |
2019 Q3
11 quarters
|
|
|
ONCR
18
DELISTED
Oncorus, Inc.
ONCR
| $2.98M | 1.14% |
2,367,436
-50,000
| -2% | -$67.9K |
2020 Q4
6 quarters
|
|
19
Larimar Therapeutics
LRMR
$263M
| $2.97M | 1.13% |
1,515,148
| – | – |
2020 Q2
8 quarters
|
|
20
Keros Therapeutics
KROS
$231M
| $2.86M | 1.09% |
103,429
+41,200
| +66% | +$1.81M |
2020 Q2
8 quarters
|
|
21
Corvus Pharmaceuticals
CRVS
$849M
| $2.19M | 0.84% |
2,214,184
+511,047
| +30% | +$627K |
2019 Q3
11 quarters
|
|
22
Entrada Therapeutics
TRDA
$214M
| $1.99M | 0.76% |
+163,496
| New | +$1.24M |
2022 Q2
0 quarters
|
|
23
Ovid Therapeutics
OVID
$473M
| $1.86M | 0.71% |
864,822
+11,934
| +1% | +$28.8K |
2019 Q3
11 quarters
|
|
|
EIGR
24
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $1.2M | 0.46% |
+6,333
| New | +$1.28M |
2022 Q2
0 quarters
|
|
|
PHAS
25
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
| $450K | 0.17% |
+750,000
| New | +$718K |
2022 Q2
0 quarters
|
|
Similar funds
SC
T
W
RBGI
TOGEPT
IAM
RCGI
AEPLI
CHI Advisors's Q2 2022 Portfolio in Review
As of Q2 2022, CHI Advisors held 28 positions worth $262M, up 11% from $235M the previous quarter. Its ten largest holdings account for 83% of the portfolio.
CHI Advisors deployed $49.5M of net new capital in Q2 2022, opening 6 new positions and adding to 13 existing holdings. Its largest new stake was Nkarta: 358,013 shares worth $4.41M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Oncorus, Inc., an estimated $67.9K trimmed.
- CHI Advisors's largest Q2 2022 buy was Nkarta: 358,013 shares worth $4.41M.
- CHI Advisors added most to Kezar Life Sciences in Q2 2022, an estimated $13.5M increase.
- CHI Advisors's biggest Q2 2022 reduction was Oncorus, Inc., cutting an estimated $67.9K.
- CHI Advisors's ten largest holdings make up 83% of its $262M portfolio in Q2 2022.
- CHI Advisors opened 6 new positions and closed 0 in Q2 2022.
- CHI Advisors's portfolio value rose 11% quarter-over-quarter to $262M.
Based on CHI Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.